Korean J Urol.  1994 Dec;35(12):1333-1338.

A Comparison of Prophylactic Efficacy of Intravesical Instillation with Bacillus Calmette-Guerin and Thiotepa in Superficial Bladder Cancer

• Park SM
• Park KS
• Park YI

Abstract

We compared the prophylactic efficacy of intravesical BCG with thiotepa instillation after complete removal of superficial bladder cancer. Forty patients received BCG and 32 received thiotepa. The mean followup period was 29 months in BCG group, and 34 months in thiotepa group. The overall recurrence rate was 35% in BCG group compared with 53% in thiotepa group, showing difference statistically(p<0.05) The mean time to recurrence was 8.7 months in BCG group, and 7.2 months in thiotepa group(p>0.05). The overall recurrence index per 100 patient-months was also lower for the BCG versus the thiotepa group(1.21 versus 1.56, p>0.05). One patient in the BCG group and 4 in the thiotepa group had recurrent tumors with progression in stage. Side effects were irritative voiding symptoms(100%), fever and chills(10%), and inguinal lymphadenitis(2.5%) in BCG group, while irritative voiding symptoms(25%), fever and chills(6.3%), and myelosuppression (6.3%) in thiotepa group. Our results suggest that BCG is significantly superior to thiotepa in reducing bladder tumor recurrence and in retarding tumor progression.

Keyword

Intravesical therapy; Superficial bladder tumor; BCG; Thiotepa

MeSH Terms

Administration, Intravesical*
Bacillus*
Fever
Follow-Up Studies
Humans
Mycobacterium bovis
Recurrence
Thiotepa*
Urinary Bladder Neoplasms*
Urinary Bladder*
Thiotepa